The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Open accessAbstract
BACKGROUND: Early clinical studies suggested that the anti-interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis. METHODS: In two phase 3 studies (AMAGINE-2 and AMAGINE-3), patients with moderate-to-severe psoriasis were randomly assigned to receive brodalumab (210 mg or 140 mg every 2 weeks), ustekinumab (45 mg for patients with a body weight ≤100 kg and 90 mg for patients >100 kg), or placebo. At week 12, patients receiving brodalumab were randomly assigned again to receive a brodalumab maintenance dose of 210 mg every 2 weeks or 140 mg every 2 weeks, every 4 weeks, or every 8 weeks; patients receiving ustekinumab continued to receive ustekinumab every 12 weeks, and patients receiving placebo received 210 mg of brodalumab every 2 weeks. The primary aims were to evaluate the superiority of brodalumab over placebo at week 12 with respect to at least a 75% reduction in the psoriasis area-and-severity index score (PASI 75) and a static physician's global assessment (sPGA) score of 0 or 1 (clear or almost clear skin), as well as the superiority of brodalumab over ustekinumab at week 12 with respect to a 100% reduction in PASI score (PASI 100). RESULTS: At week 12, the PASI 75 response rates were higher with brodalumab at the 210-mg and 140-mg doses than with placebo (86% and 67%, respectively, vs. 8% [AMAGINE-2] and 85% and 69%, respectively, vs. 6% [AMAGINE-3]; P<0.001); the rates of sPGA scores of 0 or 1 were also higher with brodalumab (P<0.001). The week 12 PASI 100 response rates were significantly higher with 210 mg of brodalumab than with ustekinumab (44% vs. 22% [AMAGINE-2] and 37% vs. 19% [AMAGINE-3], P<0.001). The PASI 100 response rates with 140 mg of brodalumab were 26% in AMAGINE-2 (P=0.08 for the comparison with ustekinumab) and 27% in AMAGINE-3 (P=0.007). Rates of neutropenia were higher with brodalumab and with ustekinumab than with placebo. Mild or moderate candida infections were more frequent with brodalumab than with ustekinumab or placebo. Through week 52, the rates of serious infectious episodes were 1.0 (AMAGINE-2) and 1.3 (AMAGINE-3) per 100 patient-years of exposure to brodalumab. CONCLUSIONS: Brodalumab treatment resulted in significant clinical improvements in patients with moderate-to-severe psoriasis. (Funded by Amgen; AMAGINE-2 and AMAGINE-3 ClinicalTrials.gov numbers, NCT01708603 and NCT01708629.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ye, P., Rodriguez, F. H., Kanaly, S., Stocking, K. L., Schurr, J., Schwarzenberger, P., Oliver, P., Huang, W., Zhang, P., Zhang, J., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.519 · Cited by 1,521
Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells
Lowes, M. A., Kikuchi, T., Fuentes-Duculan, J., Cardinale, I., Zaba, L. C., Haider, A. S., Bowman, E. P., & Krueger, J. G. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701213 · Cited by 1,082
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056
Conti, H. R., Shen, F., Nayyar, N., Stocum, E., Sun, J. N., Lindemann, M. J., Ho, A. W., Hai, J. H., Yu, J. J., Jung, J. W., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081463 · Cited by 1,024
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109017 · Cited by 941
Self-citationDefinition of treatment goals for moderate to severe psoriasis: a European consensus
Mrowietz, U., Kragballe, K., Reich, K., Spuls, P., Griffiths, C. E. M., Nast, A., Franke, J., Antoniou, C., Arenberger, P., Balieva, F., et al. (2011) · Archives of Dermatological Research · doi:10.1007/s00403-010-1080-1 · Cited by 898
Nograles, K. E., Zaba, L. C., Guttman-Yassky, E., Fuentes-Duculan, J., Suárez-Fariñas, M., Cardinale, I., Khatcherian, A., Gonzalez, J., Pierson, K. C., White, T. R., et al. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08769.x · Cited by 804
Teunissen, M. B. M., Bos, J. D., Koomen, C. W., de Waal Malefyt, R., & Wierenga, E. A. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00347.x · Cited by 570
Lebwohl, M. G., Bachelez, H., Barker, J., Girolomoni, G., Kavanaugh, A., Langley, R. G., Paul, C. F., Puig, L., Reich, K., & van de Kerkhof, P. C. M. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.12.018 · Cited by 515
Self-citationIL-17C regulates the innate immune function of epithelial cells in an autocrine manner
Ramirez-Carrozzi, V., Sambandam, A., Luis, E., Lin, Z., Jeet, S., Lesch, J., Hackney, J., Kim, J., Zhou, M., Lai, J., et al. (2011) · Nature Immunology · doi:10.1038/ni.2156 · Cited by 477
Cited by
Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. N. W. N. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32549-6 · Cited by 2,383
Self-citationPathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review
Armstrong, A. W., & Read, C. (2020) · JAMA · doi:10.1001/jama.2020.4006 · Cited by 2,335
Self-citationPsoriasis pathogenesis and the development of novel targeted immune therapies
Hawkes, J. E., Chan, T. C., & Krueger, J. G. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.004 · Cited by 972
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.057 · Cited by 969
Self-citationGreb, J. E., Goldminz, A. M., Elder, J. T., Lebwohl, M. G., Gladman, D. D., Wu, J. J., Mehta, N. N., Finlay, A. Y., & Gottlieb, A. B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.82 · Cited by 922
Self-citationBlauvelt, A., Papp, K. A., Griffiths, C. E. M., Randazzo, B., Wasfi, Y., Shen, Y.-K., Li, S., & Kimball, A. B. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.11.041 · Cited by 897
Self-citationThe Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Blauvelt, A., & Chiricozzi, A. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-018-8702-3 · Cited by 789
Reich, K., Armstrong, A. W., Foley, P., Song, M., Wasfi, Y., Randazzo, B., Li, S., Shen, Y.-K., & Gordon, K. B. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.11.042 · Cited by 761
Self-citationGuttman-Yassky, E., Bissonnette, R., Ungar, B., Suárez-Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y., Xu, H., Peng, X., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 697
Self-citationTherapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00184-7 · Cited by 668
The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Brunner, P. M., Guttman-Yassky, E., & Leung, D. Y. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.011 · Cited by 642
Vitiligo: Mechanisms of Pathogenesis and Treatment
Frisoli, M. L., Essien, K., & Harris, J. E. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100919-023531 · Cited by 618
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
Hawkes, J. E., Yan, B. Y., Chan, T. C., & Krueger, J. G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800013 · Cited by 593
Reich, K., Papp, K. A., Blauvelt, A., Tyring, S. K., Sinclair, R., Thaçi, D., Nograles, K., Mehta, A., Cichanowitz, N., Li, Q., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31279-5 · Cited by 569
Self-citationSingh, J. A., Guyatt, G., Ogdie, A., Gladman, D. D., Deal, C., Deodhar, A., Dubreuil, M., Dunham, J., Husni, M. E., Kenny, S., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40726 · Cited by 493
Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions
Patel, D. D., & Kuchroo, V. K. (2015) · Immunity · doi:10.1016/j.immuni.2015.12.003 · Cited by 486
The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
Brembilla, N. C., Senra, L., & Boehncke, W.-H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01682 · Cited by 475
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
Moschen, A. R., Tilg, H., & Raine, T. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0084-8 · Cited by 473
Singh, J. A., Guyatt, G., Ogdie, A., Gladman, D. D., Deal, C., Deodhar, A., Dubreuil, M., Dunham, J., Husni, M. E., Kenny, S., et al. (2019) · Arthritis Care & Research · doi:10.1002/acr.23789 · Cited by 466
Zhang, Y., Chandra, V., Riquelme Sanchez, E., Dutta, P., Quesada, P. R., Rakoski, A., Zoltan, M., Arora, N., Baydogan, S., Horne, W., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190354 · Cited by 448
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., Mazaud, C., Droitcourt, C., Hughes, C., Ingram, J. R., Naldi, L., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub2 · Cited by 433
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
Nast, A., Smith, C., Spuls, P. I., Avila Valle, G., Bata‐Csörgö, Z., Boonen, H., De Jong, E., Garcia‐Doval, I., Gisondi, P., Kaur‐Knudsen, D., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16915 · Cited by 420
Furue, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155382 · Cited by 419
Neuromodulation by the immune system: a focus on cytokines
Salvador, A. F., de Lima, K. A., & Kipnis, J. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00508-z · Cited by 389
IL-17 in Chronic Inflammation: From Discovery to Targeting
Beringer, A., Noack, M., & Miossec, P. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.01.001 · Cited by 402
The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis
Dainichi, T., Kitoh, A., Otsuka, A., Nakajima, S., Nomura, T., Kaplan, D. H., & Kabashima, K. (2018) · Nature Immunology · doi:10.1038/s41590-018-0256-2 · Cited by 395
Targan, S. R., Feagan, B., Vermeire, S., Panaccione, R., Melmed, G. Y., Landers, C., Li, D., Russell, C., Newmark, R., Zhang, N., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.298 · Cited by 383
Self-citationReich, K., Armstrong, A. W., Langley, R. G., Flavin, S., Randazzo, B., Li, S., Hsu, M.-C., Branigan, P., & Blauvelt, A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31773-8 · Cited by 381
Self-citationBaker, K. F., & Isaacs, J. D. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211555 · Cited by 370
Psoriasis: Which therapy for which patient
Kaushik, S. B., & Lebwohl, M. G. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.057 · Cited by 368
Self-citationLangley, R. G., Tsai, T. ‐., Flavin, S., Song, M., Randazzo, B., Wasfi, Y., Jiang, J., Li, S., & Puig, L. (2018) · British Journal of Dermatology · doi:10.1111/bjd.15750 · Cited by 341
Self-citationReich, K., Papp, K. A., Blauvelt, A., Langley, R. G., Armstrong, A., Warren, R. B., Gordon, K. B., Merola, J. F., Okubo, Y., Madden, C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00125-2 · Cited by 315
Self-citationThe role of IL‐23 and the IL‐23/TH17 immune axis in the pathogenesis and treatment of psoriasis
Girolomoni, G., Strohal, R., Puig, L., Bachelez, H., Barker, J., Boehncke, W. H., & Prinz, J. C. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14433 · Cited by 313
Self-citationInterleukin-17A and Keratinocytes in Psoriasis
Furue, M., Furue, K., Tsuji, G., & Nakahara, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041275 · Cited by 300
Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis
Armstrong, A. W., Puig, L., Joshi, A., Skup, M., Williams, D., Li, J., Betts, K. A., & Augustin, M. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.4029 · Cited by 294
Self-citationRole of IL‐25, IL‐33, and TSLP in triggering united airway diseases toward type 2 inflammation
Hong, H., Liao, S., Chen, F., Yang, Q., & Wang, D. (2020) · Allergy · doi:10.1111/all.14526 · Cited by 272
Saunte, D. M., Mrowietz, U., Puig, L., & Zachariae, C. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15015 · Cited by 270
Self-citationWinthrop, K. L., Mariette, X., Silva, J. T., Benamu, E., Calabrese, L. H., Dumusc, A., Smolen, J. S., Aguado, J. M., & Fernández-Ruiz, M. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.002 · Cited by 259
Fujita, H., Terui, T., Hayama, K., Akiyama, M., Ikeda, S., Mabuchi, T., Ozawa, A., Kanekura, T., Kurosawa, M., Komine, M., et al. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14523 · Cited by 254
Host Control of Fungal Infections: Lessons from Basic Studies and Human Cohorts
Lionakis, M. S., & Levitz, S. M. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053318 · Cited by 209
The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Singh, R., Koppu, S., Perche, P. O., & Feldman, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312793 · Cited by 192
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
Lebwohl, M. G., Papp, K. A., Marangell, L. B., Koo, J., Blauvelt, A., Gooderham, M., Wu, J. J., Rastogi, S., Harris, S., Pillai, R., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.08.024 · Cited by 179
“Psychiatric AEs were observed, including depression and anxiety, and SIB incidents were reported.(16,17,19) Although there is no known biologic basis for brodalumab to induce psychiatric AEs, the possibility of drug-mediated effects on patient behavior warranted further investigation.”
Self-citationWang, M., Zhang, S., Zheng, G., Huang, J., Songyang, Z., Zhao, X., & Lin, X. (2018) · Immunity · doi:10.1016/j.immuni.2018.05.012 · Cited by 155
Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective
Zwicky, P., Unger, S., & Becher, B. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191123 · Cited by 91
Tomalin, L. E., Kim, J., Correa da Rosa, J., Lee, J., Fitz, L. J., Berstein, G., Valdez, H., Wolk, R., Krueger, J. G., & Suárez-Fariñas, M. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.09.023 · Cited by 46
Bai, J. P. F., Schmidt, B. J., Gadkar, K. G., Damian, V., Earp, J. C., Friedrich, C., van der Graaf, P. H., Madabushi, R., Musante, C. J., Naik, K., et al. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00585-x · Cited by 38
Two-year US Pharmacovigilance report on Brodalumab
Lebwohl, M., Leonardi, C., Wu, J. J., Armstrong, A., Rawnsley, N., Merchant, M., Alexander, B., & Jacobson, A. (2021) · Dermatology and Therapy · doi:10.1007/s13555-020-00472-x · Cited by 24
Self-citationMonoclonal Antibodies: A Prospective and Retrospective View
Sivaccumar, J., Sandomenico, A., Vitagliano, L., & Ruvo, M. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200219142231 · Cited by 14
Metadata
- Authors
- Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., Armstrong, A. W., Stingl, G., Kimball, A. B., Bachelez, H., Wu, J. J., Crowley, J., Langley, R. G., Blicharski, T., Paul, C., Lacour, J.-P., Tyring, S., Kircik, L., Chimenti, S., Callis Duffin, K., Bagel, J., Koo, J., Aras, G., Li, J., Song, W., Milmont, C. E., Shi, Y., Erondu, N., Klekotka, P., Kotzin, B., & Nirula, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-10
- Volume
- 373
- Issue
- 14
- Pages
- 1318-1328
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2326643498
- Cited by
- 828
- References
- 21
- FWCI
- 36.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.